Active brain changes after initiating fingolimod therapy in multiple sclerosis patients using individual voxel-based analyses for diffusion tensor imaging
نویسندگان
چکیده
Voxel-based analysis (VBA) of diffusion tensor images (DTI) and voxel-based morphometry (VBM) in patients with multiple sclerosis (MS) can sensitively detect occult tissue damage that underlies pathological changes in the brain. In the present study, both at the start of fingolimod and post-four months clinical remission, we assessed four patients with MS who were evaluated with VBA of DTI, VBM, and fluid-attenuated inversion recovery (FLAIR). DTI images for all four patients showed widespread areas of increased mean diffusivity (MD) and decreased fractional anisotropy (FA) that were beyond the high-intensity signal areas across images. After four months of continuous fingolimod therapy, DTI abnormalities progressed; in particular, MD was significantly increased, while brain volume and high-intensity signals were unchanged. These findings suggest that VBA of DTI (e.g., MD) may help assess MS demyelination as neuroinflammatory conditions, even though clinical manifestations of MS appear to be in complete remission during fingolimod.
منابع مشابه
Pathological Assessment of Brain White Matter in Relapsing-Remitting MS Patients using Quantitative Magnetization Transfer Imaging
Introduction: Multiple sclerosis (MS) is characterized by lesions in the white matter (WM) of the central nervous system. Magnetic resonance imaging is the most specific and sensitive method for diagnosis of multiple sclerosis. However, the ability of conventional MRI to show histopathologic heterogeneity of MS lesions is insufficient. Quantitative magnetization transfer imaging (qMTI) is a rel...
متن کاملبررسی تاثیر داروی فینگولیمود بر تعداد پلاک های مغز بیماران مالتیپل اسکلروز قبل و پس از درمان در تصویربرداری تشدید میدان مغناطیسی
Background: Several treatments have been proposed to control Multiple Sclerosis (MS). Fingolimod is the first oral medication for the disease that was approval by Food and Drug Administration American (FDA) since 2010 and is produced in Iran from October 2013. The aim of this study was evaluation of the effect of fingolimod on the number of brain plaque in multiple sclerosis patients before and...
متن کاملSensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
Introduction: Multiple sclerosis (MS) is a lifelong disease of the brain and spinal cord. Fingolimod is an oral drug which modulates the S1P receptor and is used for relapsing remitting form of MS and can causes rebound activity if it is ceased even in a short period of washout time. Case Report: Here, we introduce a young girl, a known case of MS, who developed revers...
متن کاملEvaluation of the relationship between axon injury and clinical symptoms in patients with multiple sclerosis using diffusion tensor MRI imaging
Background: Magnetic resonance imaging (MRI) is a non-invasive imaging technology that shows detailed anatomical and pathological images. It is often used for disease detection, diagnosis, and treatment monitoring, in particular with neurodegenerative diseases, such as Multiple sclerosis (MS), Alzheimer's and amyotrophic lateral sclerosis. However, conventional MRI provides only qualitative inf...
متن کاملImpact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
OBJECTIVE To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study. DESIGN Patients with active relapsing-remitting multiple sclerosis were randomized to receive fingolimod, 0.5 mg; fingolimod, 1.25 mg; or placebo for 2 years. Standardized magne...
متن کامل